Related Experiment Video
Updated: Feb 8, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Phase I and Biomarker Study of Plerixafor and Bevacizumab in Recurrent High-Grade Glioma
Eudocia Q Lee1,2, Dan G Duda2,3, Alona Muzikansky3
1Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts. eqlee@partners.org.
Abstract:
Purpose: Although antiangiogenic therapy for high-grade glioma (HGG) is promising, responses are not durable. Correlative clinical studies suggest that the SDF-1α/CXCR4 axis may mediate resistance to VEGFR inhibition. Preclinical data have demonstrated that plerixafor (a reversible CXCR4 inhibitor) could inhibit glioma progression after anti-VEGF pathway inhibition. We conducted a phase I study to determine the safety of plerixafor and bevacizumab in recurrent HGG.Patients and Methods: Part 1 enrolled 23 patients with a 3 × 3 dose escalation design to a maximum planned dose of plerixafor 320 μg/kg subcutaneously on days 1 to 21 and bevacizumab 10 mg/kg intravenously on days 1 and 15 of each 28-day cycle. Cerebrospinal fluid (CSF) and plasma samples were obtained for pharmacokinetic analyses. Plasma and cellular biomarkers were evaluated before and after treatment. Part 2 enrolled 3 patients and was a surgical study to determine plerixafor's penetration in tumor tissue.Results: In Part 1, no dose-limiting toxicities were seen at the maximum planned dose of plerixafor + bevacizumab. Treatment was well tolerated. After plerixafor 320 μg/kg treatment, the average CSF drug concentration was 26.8 ± 19.6 ng/mL. Plerixafor concentration in resected tumor tissue from patients pretreated with plerixafor was 10 to 12 μg/g. Circulating biomarker data indicated that plerixafor + bevacizumab induces rapid and persistent increases in plasma SDF-1α and placental growth factor. Progression-free survival correlated with pretreatment plasma soluble mesenchymal-epithelial transition receptor and sVEGFR1, and overall survival with the change during treatment in CD34+ progenitor/stem cells and CD8 T cells.Conclusions: Plerixafor + bevacizumab was well tolerated in HGG patients. Plerixafor distributed to both the CSF and brain tumor tissue, and treatment was associated with biomarker changes consistent with VEGF and CXCR4 inhibition. Clin Cancer Res; 24(19); 4643-9. ©2018 AACR.
Insights
This phase I study found that plerixafor and bevacizumab combination therapy is safe and well-tolerated in patients with high-grade glioma (HGG). The treatment showed promising biomarker changes and drug distribution to the central nervous system.
Area of Science:
- Oncology
- Pharmacology
- Neuroscience
Background:
- Antiangiogenic therapy for high-grade glioma (HGG) shows limited durability.
- The SDF-1α/CXCR4 axis is implicated in resistance to VEGFR inhibitors.
- Plerixafor, a CXCR4 inhibitor, demonstrated potential in preclinical models of glioma.
Purpose of the Study:
- To assess the safety and tolerability of combining plerixafor and bevacizumab in recurrent HGG.
- To evaluate drug distribution into cerebrospinal fluid (CSF) and tumor tissue.
- To investigate associated biomarker changes during treatment.
Main Methods:
- Phase I dose escalation study (Part 1) with 23 HGG patients.
- Combination therapy: plerixafor (320 μg/kg SC) and bevacizumab (10 mg/kg IV) in 28-day cycles.
- Pharmacokinetic and biomarker analyses of plasma and CSF; tumor tissue analysis in 3 patients (Part 2).
Main Results:
- The combination was well-tolerated with no dose-limiting toxicities at the maximum dose.
- Plerixafor achieved significant concentrations in CSF (26.8 ± 19.6 ng/mL) and tumor tissue (10-12 μg/g).
- Biomarker analysis revealed increased SDF-1α and placental growth factor; survival correlated with specific cell populations and soluble factors.
Conclusions:
- Plerixafor and bevacizumab combination therapy is safe and well-tolerated in recurrent HGG patients.
- Plerixafor effectively penetrates the central nervous system, including brain tumors.
- The combination induces biomarker changes indicative of VEGF and CXCR4 inhibition, warranting further investigation.
Related Concept Videos
Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Graded Potential
Graded potentials fall into two categories: depolarizing and hyperpolarizing. Depolarizing graded potentials typically occur when sodium (Na+) or...
Types of Aggregate Grading
Well-graded aggregates include a complete range of necessary size fractions that fit together to create a dense matrix with minimal voids, represented by a smooth, continuous gradation curve. This type of grading ensures good...
Phase Diagrams
Phase Transitions
Sieve Analysis and Grading Curves

